Agios Pharma (8AP) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

8AP Analyst Ratings

Moderate Buy

6 Buy

3 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Agios

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

8AP Stock 12 Month Forecast

Average Price Target

€35.62

▲(14.16% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Agios Pharma in the last 3 months. The average price target is €35.62 with a high forecast of €47.78 and a low forecast of €26.93. The average price target represents a 14.16% change from the last price of €31.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","48":"€48","27.75":"€27.8","34.5":"€34.5","41.25":"€41.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.78071595,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€47.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.61835189,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€35.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.93094899,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€26.93</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,27.75,34.5,41.25,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32,33.21390122692308,34.427802453846155,35.64170368076923,36.85560490769231,38.06950613461539,39.283407361538465,40.497308588461536,41.71120981538462,42.92511104230769,44.139012269230776,45.352913496153846,46.566814723076924,{"y":47.78071595,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32,32.27833476076923,32.55666952153846,32.83500428230769,33.11333904307692,33.39167380384615,33.67000856461539,33.94834332538461,34.226678086153846,34.50501284692308,34.783347607692306,35.06168236846154,35.340017129230766,{"y":35.61835189,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32,31.61007299923077,31.22014599846154,30.830218997692306,30.440291996923076,30.050364996153846,29.660437995384616,29.270510994615385,28.880583993846155,28.490656993076925,28.10072999230769,27.71080299153846,27.32087599076923,{"y":26.93094899,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€47.78

Average Price Target€35.62

Lowest Price Target€26.93

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

€35.62→€33.88

Buy

8.59%

Upside

Reiterated

07/31/26

Truist Financial Keeps Their Buy Rating on Agios Pharma (AGIO)

Samantha Semenkow

Citi

€39.96→€45.17

Buy

44.79%

Upside

Reiterated

07/31/26

Agios Pharmaceuticals price target raised to $52 from $46 at CitiAgios Pharmaceuticals price target raised to $52 from $46 at Citi

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

07/30/26

Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating

Alec Stranahan

Bank of America Securities

€39.96

Buy

28.08%

Upside

Reiterated

07/30/26

Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46

Emily Bodnar

H.C. Wainwright

€45.17→€47.78

Buy

53.14%

Upside

Reiterated

07/30/26

Agios Pharmaceuticals price target raised to $55 from $52 at H.C. WainwrightAgios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright

Luca Issi

RBC Capital

€27.8

Hold

-10.90%

Downside

Reiterated

07/30/26

RBC Capital Sticks to Their Hold Rating for Agios Pharma (AGIO)

Salveen Richter

Goldman Sachs

€27.8

Hold

-10.90%

Downside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO) and Imunon (NASDAQ: IMNN)

Andrew Berens

Leerink Partners

―

Buy

―

Reiterated

07/07/26

Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)

Tessa Romero

J.P. Morgan

€31.27→€26.93

Hold

-13.68%

Downside

Assigned

06/11/26

Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)

Greg Harrison

Scotiabank

€56.47

Buy

80.99%

Upside

Reiterated

08/05/25

Scotiabank Remains a Buy on Agios Pharma (AGIO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

€35.62→€33.88

Buy

8.59%

Upside

Reiterated

07/31/26

Truist Financial Keeps Their Buy Rating on Agios Pharma (AGIO)

Samantha Semenkow

Citi

€39.96→€45.17

Buy

44.79%

Upside

Reiterated

07/31/26

Agios Pharmaceuticals price target raised to $52 from $46 at CitiAgios Pharmaceuticals price target raised to $52 from $46 at Citi

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

07/30/26

Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating

Alec Stranahan

Bank of America Securities

€39.96

Buy

28.08%

Upside

Reiterated

07/30/26

Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46

Emily Bodnar

H.C. Wainwright

€45.17→€47.78

Buy

53.14%

Upside

Reiterated

07/30/26

Agios Pharmaceuticals price target raised to $55 from $52 at H.C. WainwrightAgios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright

Luca Issi

RBC Capital

€27.8

Hold

-10.90%

Downside

Reiterated

07/30/26

RBC Capital Sticks to Their Hold Rating for Agios Pharma (AGIO)

Salveen Richter

Goldman Sachs

€27.8

Hold

-10.90%

Downside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO) and Imunon (NASDAQ: IMNN)

Andrew Berens

Leerink Partners

―

Buy

―

Reiterated

07/07/26

Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)

Tessa Romero

J.P. Morgan

€31.27→€26.93

Hold

-13.68%

Downside

Assigned

06/11/26

Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)

Greg Harrison

Scotiabank

€56.47

Buy

80.99%

Upside

Reiterated

08/05/25

Scotiabank Remains a Buy on Agios Pharma (AGIO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agios Pharma

3 Months

Andrew BerensLeerink Partners

Success Rate

11/16 ratings generated profit

Average Return

+6.44%

Copying Andrew Berens's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +6.44% per trade.

1 Year

Andrew BerensLeerink Partners

Success Rate

10/16 ratings generated profit

Average Return

+22.06%

Copying Andrew Berens's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +22.06% per trade.

2 Years

Andrew BerensLeerink Partners

Success Rate

14/16 ratings generated profit

Average Return

+50.22%

Copying Andrew Berens's trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +50.22% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8AP Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 8AP has received 26 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 8AP average Analyst price target in the past 3 months is 35.62.

Each month's total comprises the sum of three months' worth of ratings.

8AP Financial Forecast

8AP Earnings Forecast

Next quarter’s earnings estimate for 8AP is -€1.11 with a range of -€1.54 to -€0.78. The previous quarter’s EPS was -€1.47. 8AP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.

8AP Sales Forecast

Next quarter’s sales forecast for 8AP is €44.48M with a range of €22.02M to €56.36M. The previous quarter’s sales results were €38.80M. 8AP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.

8AP Stock Forecast FAQ

What is DE:8AP’s average 12-month price target, according to analysts?

Based on analyst ratings, Agios Pharma’s 12-month average price target is 35.62.

What is DE:8AP’s upside potential, based on the analysts’ average price target?

Agios Pharma has 14.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Agios Pharma a Buy, Sell or Hold?

Agios Pharma has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Agios Pharma’s share price target?

The average share price target for Agios Pharma is 35.62. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €47.78 ,and the lowest forecast is €26.93. The average share price target represents 14.16% Increase from the current price of €31.2.

What do analysts say about Agios Pharma?

Agios Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Agios Pharma?

To buy shares of DE:8AP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Agios Pharma (8AP) Stock Forecast & Price Target

8AP Analyst Ratings

8AP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Agios Pharma

8AP Analyst Recommendation Trends

8AP Financial Forecast

8AP Earnings Forecast

8AP Sales Forecast

8AP Stock Forecast FAQ

Detailed List of Analyst Forecasts